Abivax publishes financial reports with the French and U.S. securities regulatory agencies
Abivax Announces Full Year 2024 Financial Results
ABIVAX Société Anonyme (NASDAQ: ABVX) had its "equal weight" rating re-affirmed by analysts at Morgan Stanley. They now have a $12.00 price target on the stock.
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025
Abivax Publishes 2025 Financial Calendar